Fosun Health Chen Qiyu: Internet medical company to invest in the future
Internet medical has several exploration directions - O2O, Internet medical treatment solves the problem of uneven distribution of medical systems, but the model is unknown, and there are certain barriers to resource docking. In the field of medical services, there are many pain points in doctor-patient relationship and medical insurance payment ability, which need to be solved. Fosun's large health industry carries the grand strategic requirements of Fosun Group. The big health industry has been developed in the Fosun system for more than 20 years, and it is a section with deep industrial depth. The board of directors of Fosun Group has high requirements for the big health sector and also set future goals. In the future, under the help of medical products , medical services, health insurance, distribution retail and the Internet, Fosun’s goal of health is not a dream too far. It depends on the Chinese market and has a chance to achieve it. Valuable and achievable pain points are the core of industrial development In the process of achieving the goal, we must pay special attention to precision medicine , innovative research and development, maintain the leading position of Fosun's big health industry in the Chinese market, accelerate the development of China's hospital network construction, and actively create a closed-loop model of insurance and medical care. In the process of development, enterprises must continue to look for pain points in the future. Finding the pain points that are truly valuable and achievable is the core direction of industrial development. For example, in the field of big health, there are many pain points in precision medicine that need to be solved. At present, the tumor is highly developed, how to accurately diagnose it, and to ensure low trauma, effective treatment, and high quality survival? In the field of medical beauty and oral cavity, there is also a lot of room for development around the need for a more quality and more decent life. Internet medical has several exploration directions - O2O, Internet medical treatment solves the problem of uneven distribution of medical systems, but the model is unknown, and there are certain barriers to resource docking. In the field of medical services, there are many pain points in doctor-patient relationship and medical insurance payment ability, which need to be solved. Excellent team can polish products that solve pain points To solve the pain point, the most important thing is to look at the team first. A truly excellent team can identify and resolve pain points and proactively polish products that address pain points. There are two major categories of products for pain points, one is product form, from innovative technology research and development to process amplification, entering the marketing system, solving customer problems, thereby earning income; the other category is service, including insurance products. , medical products, Internet products, such products have a more difficult grinding process, because we must continue to compete with competitive products, improve customer experience, get excellent products, and solve pain points. In China, nervous system drugs are also one of the drugs with the most rapid sales growth in recent years. In 2002, nervous system drugs occupied 5.9% of the entire pharmaceutical market share, and the total sales amount increased by 9.4%. buy nootropics,nootropics benefits,nootropics for adhd,nootropics for weight loss,nootropics supplements Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropic.com
With the increasing trend of urbanization and aging, the elderly population in China has exceeded 120 million, and the incidence of geriatric diseases, especially mental diseases, is increasing year by year. With the increase of residents' income, the elderly's requirements for quality of life also increase. As a result, the demand for drugs to treat mental illnesses such as Alzheimer's has soared. In WHO drug classification, psychotropic drugs and nootropic drugs are grouped into one class. We briefly analyzed the development trend of this class of drugs through the clinical drug use data collected from more than 300 domestic key hospitals by Chinese Pharmaceutical Association.
The overall market size of this class of drugs is about 1.22 billion yuan, the consumption sum increased by 5.0% in 2002, but the sales quantity increased by 11.2%. The main reason why the consumption sum did not increase with the sales quantity is that several main varieties of this class of drugs, such as piracetam, cobalt bin amide and ginkgo biloba leaf, etc. In 2002, the price of selling units fell sharply due to bidding. Among these drugs, ginkgo biloba preparation occupies the largest market share, accounting for more than 1/3 of the market share, ganglioside ester and cobalt bin amide combined also occupy nearly 1/3 of the market share, piracetam and other "sitan" drugs occupy nearly 10% of the market share, the rest of the drugs occupy less than 5% of the market share. At present, more than 20 ginkgo leaf production enterprises, piracetam production enterprises more than 70, have entered the stage of price competition, profit repeatedly diluted.
In the first-line varieties, except ginkgo biloba leaves preparation maintained vigorous vitality, the growth of other varieties were weak, especially the traditional variety piracetam suffered from bidding